Ads
related to: statin with lowest diabetes risk freebestbloodsugar.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [22] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries. [24]
[22] [23] Another consequence of taking statins is the risk of developing new-onset diabetes, which is more prominent in individuals with high TG levels and body mass index (BMI). [19] However, the risk is far outweighed by the benefits from statin therapy for the reduction in cardiovascular outcomes. [20]
Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. [6] It is recommended to be used together with dietary changes, exercise, and weight loss. [6] It is taken orally (by mouth). [6]
Using PREVENT to calculate the 10-year risk for developing heart disease, the researchers determined that some 40% fewer people would have met the criteria for a statin prescription.
The phenolic compounds and saponins in quinoa may help reduce the risk of cardiovascular disease and diabetes, and its soluble fiber helps decrease triglycerides and LDL levels in the body while ...
A risk exists of muscle damage (myopathy and rhabdomyolysis) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85. [2] Fibrates are indicated for hypertriglyceridemia. Fibrates typically lower triglycerides by 20% to 50%.
An alternative to statins may help reduce deaths from heart disease among people with high levels of LDL, or “bad” cholesterol, new research finds.. When taken as a daily pill, bempedoic acid ...
The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP). JUPITER was the first clinical trial to indicate that statin therapy may provide benefit to patients with low-to-normal LDL levels and no known cardiovascular disease.